Top

Cancer Chemotherapy and Pharmacology

Published in:

Open Access 01-07-2009 | Original Article

Application of prolonged microdialysis sampling in carboplatin-treated cancer patients

Authors: Inge R. H. M. Konings, Frederike K. Engels, Stefan Sleijfer, Jaap Verweij, Erik A. C. Wiemer, Walter J. Loos

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2009

Abstract

Purpose

To better understand the mechanisms underlying (in)sensitivity of tumors to anticancer drugs, assessing intra-tumor drug pharmacokinetics (PKs) could be important. We explored the feasibility of microdialysis in tumor tissue for multiple days in a clinical setting, using carboplatin as model drug.

Methods

Plasma and microdialysate samples from tumor and adipose normal tissues were collected up to 47 h after dosing in eight carboplatin-treated patients with an accessible (sub)cutaneous tumor.

Results

Pharmacokinetics were evaluable in tumor tissue in 6/8 patients and in adipose normal tissue in 3/8 patients. Concentration–time curves of unbound platinum in both the tissues followed the pattern of the curves in plasma, with exposure ratios of tissue versus plasma ranging from 0.64 to 1.46.

Conclusions

Microdialysis can be successfully employed in ambulant patients for multiple days, which enables one to study tissue PK of anticancer drugs in normal and malignant tissues in more detail.

Zamboni WC, Strychor S, Joseph E, Parise RA, Egorin MJ, Eiseman JL (2008) Tumor, tissue and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer Chemother Pharmacol 62:417–426PubMedCrossRef

Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL (2007) Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res 13:7217–7223PubMedCrossRef

Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF (1999) Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 43:269–276PubMedCrossRef

Müller M (2002) Science, medicine, and the future: microdialysis. Br Med J 324:588–591CrossRef

Müller M, Mader RM, Steiner B et al (1997) 5-Fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res 57:2598–2601PubMed

Mader RM, Schrolnberger C, Rizovski B et al (2003) Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer 88:782–787PubMedCrossRef

Tegeder I, Brautigam L, Seegel M et al (2003) Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther 73:417–426PubMedCrossRef

Blochl-Daum B, Müller M, Meisinger V et al (1996) Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis. Br J Cancer 73:920–924PubMed

Joukhadar C, Klein N, Mader RM et al (2001) Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma. Cancer 92:2190–2196PubMedCrossRef

10.

Ekström PO, Andersen A, Saeter G et al (1997) Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: a case report. Cancer Chemother Pharmacol 39:267–272PubMed

11.

Müller M, Brunner M, Schmid R et al (1998) Interstitial methotrexate kinetics in primary breast cancer lesions. Cancer Res 58:2982–2985PubMed

12.

Long DF, Repta AJ (1981) Cisplatin: chemistry, distribution and biotransformation. Biopharm Drug Dispos 2:1–16PubMedCrossRef

13.

Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed

14.

Müller M, Schmid R, Georgopoulos A et al (1995) Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 57:371–380PubMedCrossRef

15.

Chaurasia CS, Müller M, Bashaw ED et al (2007) AAPS-FDA Workshop White Paper: microdialysis principles, application and regulatory perspectives. Pharm Res 24:1014–1025PubMedCrossRef

16.

Ault JM, Riley CM, Meltzer NM et al (1994) Dermal microdialysis sampling in vivo. Pharm Res 11:1631–1639PubMedCrossRef

17.

Kitzen JJ, Verweij J, Wiemer EA et al (2006) The relevance of microdialysis for clinical oncology. Curr Clin Pharmacol 1:255–263PubMedCrossRef

18.

Loos WJ, Zamboni WC, Engels FK et al (2007) Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel. J Pharm Biomed Anal 45:288–294PubMedCrossRef

19.

Loos WJ, de Jongh FE, Sparreboom A et al (2006) Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 24:1499–1506PubMedCrossRef

20.

Ma J, Stoter G, Verweij J, Schellens JH (1996) Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol 38:391–394PubMedCrossRef

21.

Johnsson A, Björk H, Schütz A, Skärby T (1998) Sample handling for determination of free platinum in blood after cisplatin exposure. Cancer Chemother Pharmacol 41:248–251PubMedCrossRef

22.

Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320PubMedCrossRef

23.

Heldin CH, Rubin K, Pietras K et al (2004) High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer 4:806–813PubMedCrossRef

24.

Less JR, Posner MC, Boucher Y et al (1992) Interstitial hypertension in human breast and colorectal tumors. Cancer Res 52:6371–6374PubMed

25.

Nathanson SD, Nelson L (1994) Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann Surg Oncol 1:333–338PubMed

26.

Boucher Y, Kirkwood JM, Opacic D et al (1991) Interstitial hypertension in superficial metastatic melanoma in humans. Cancer Res 51:6691–6694PubMed

27.

Gutmann R, Leunig M, Feyh J, Goetz AE et al (1992) Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 52:1993–1995PubMed

28.

Kristjansen PE, Boucher Y, Jain RK (1993) Dexamethasone reduces the interstitial fluid pressure in humon colon adenocarcinoma xenograft. Cancer Res 53:4764–4766PubMed

29.

Stuhr LEB, Salnikow AV, Iversen VV et al (2006) High-dose, short-term, anti-inflammatory treatment with dexamethasone reduces tumorgrowth and augments the effects of 5-fluorouracil on dimethyl-α-benzanthrace-induced mammary tumors in rats. Scand J Clin Lab Invest 66:477–486PubMedCrossRef

30.

Zamboni WC, Gervais AC, Egorin MJ et al (2004) Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53:329–336PubMedCrossRef

31.

Zamboni WC, Stewart CF, Thompson J et al (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505–511PubMedCrossRef

Title: Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
Authors: Inge R. H. M. Konings
Frederike K. Engels
Stefan Sleijfer
Jaap Verweij
Erik A. C. Wiemer
Walter J. Loos
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0898-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2009

Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells

RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines

Prolonged accumulation of high-dose methotrexate in a case with large liver cysts

Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis

The x c − cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine

Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens

Keynote webinar | Spotlight on antibody–drug conjugates in cancer